Mizuho Medy Co Ltd
TSE:4595
Net Margin
Mizuho Medy Co Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| JP |
|
Mizuho Medy Co Ltd
TSE:4595
|
34.4B JPY |
33%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
227.5B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
180.9B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
148.5B USD |
11%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
140.2B USD |
13%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
114.2B USD |
13%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
66.3B USD |
8%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
56.7B EUR |
9%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
41.9B USD |
77%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
291.8B CNY |
33%
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
37.3B USD |
10%
|
Mizuho Medy Co Ltd
Glance View
Mizuho Medy Co., Ltd. engages in the research, development, manufacture and distribution of in-vitro diagnostic products. The company is headquartered in Tosu-Shi, Saga-Ken and currently employs 173 full-time employees. The company went IPO on 2015-12-17. The firm mainly provides in-vitro diagnostic pharmaceuticals, including immune serum test drugs, biochemical test drugs, urine and feces test drugs, microbial test drugs, blood test drugs, pathological test drugs and others, in hospital and medical practitioner fields. In addition, the Company also provides over-the-counter (OTC) drugs to pharmacies and drug stores, and sells fruit tree virus test drugs to which they apply the technology of immune serology test to agricultural test centers.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Mizuho Medy Co Ltd's most recent financial statements, the company has Net Margin of 33%.
You don't have any saved screeners yet